| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EJCA.2004.09.023 |
| P698 | PubMed publication ID | 15617996 |
| P50 | author | Olaf Gefeller | Q40027859 |
| P2093 | author name string | Grange JM | |
| Shafir R | |||
| Pfahlberg A | |||
| Lambert D | |||
| Henz BM | |||
| Mastrangelo G | |||
| Rossi CR | |||
| Seebacher C | |||
| Krone B | |||
| Kokoschka EM | |||
| Kleeberg UR | |||
| Kölmel KF | |||
| Botev IN | |||
| Niin M | |||
| P433 | issue | 1 | |
| P304 | page(s) | 118-125 | |
| P577 | publication date | 2005-01-01 | |
| P1433 | published in | European Journal of Cancer | Q332260 |
| P1476 | title | Prior immunisation of patients with malignant melanoma with vaccinia or BCG is associated with better survival. An European Organization for Research and Treatment of Cancer cohort study on 542 patients | |
| P478 | volume | 41 |
| Q34512747 | Bacillus Calmette-Guérin vaccination and infant mortality |
| Q59361035 | Contemporary Approaches to In-Transit Melanoma |
| Q47576218 | Does smallpox vaccination modify HIV disease progression among ART-naive people living with HIV in Africa? |
| Q40404836 | Does yellow fever 17D vaccine protect against melanoma? |
| Q64083406 | Epidemiological and histopathological profile of malignant melanoma in Malawi |
| Q40696555 | Heterologous vaccine effects |
| Q55394839 | Human endogenous retroviruses in health and disease. |
| Q37828296 | Immune protection against tuberculosis--when is immunotherapy preferable to vaccination? |
| Q33555975 | Infections and cancer: the "fifty shades of immunity" hypothesis |
| Q37404522 | Is the risk of multiple sclerosis related to the 'biography' of the immune system? |
| Q46847441 | Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases |
| Q24627770 | Melanoma, Darwinian medicine and the inner world |
| Q30351915 | Mistletoe lectin has a shiga toxin-like structure and should be combined with other Toll-like receptor ligands in cancer therapy. |
| Q51069975 | Non-specific effect of Bacille Calmette-Guérin vaccine on the immune response to routine immunisations. |
| Q36769180 | Oncolytic viruses in cancer therapy |
| Q44025566 | Risk of lymphoma and leukaemia after bacille Calmette-Guérin and smallpox vaccination: a Danish case-cohort study |
| Q37952235 | Role of bacillus Calmette-Guérin in the treatment of advanced melanoma |
| Q38846730 | Sex-differential heterologous (non-specific) effects of vaccines: an emerging public health issue that needs to be understood and exploited |
| Q35226092 | The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies |
| Q37215621 | The use of mycobacterial adjuvant-based agents for immunotherapy of cancer |
| Q40288069 | The yellow fever 17D vaccine and risk of malignant melanoma in the United States military |
| Q24597894 | Thunder and lightning: immunotherapy and oncolytic viruses collide |
| Q104576047 | Trained immunity as a novel approach against COVID-19 with a focus on Bacillus Calmette-Guérin vaccine: mechanisms, challenges and perspectives |
| Q38312182 | Trained immunity: consequences for the heterologous effects of BCG vaccination |
| Q46489440 | Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971-2010. |
| Q34529647 | Vaccinia scars associated with better survival for adults. An observational study from Guinea-Bissau |
| Q33267272 | Vaccinia scars associated with improved survival among adults in rural Guinea-Bissau |
| Q30490366 | Yellow fever vaccine 17D administered to healthy women aged between 40 and 54 years halves breast cancer risk: an observational study |
Search more.